Educational use only
Commercial category names are not evidence that a product treats disease, slows aging, has known side-effect rates, is sterile, is legally marketed, or is FDA-approved. This page uses vendor catalogs only to map names and claimed tissue targets.
Cytomax vs Cytogen
| Question | Cytomax | Cytogen |
|---|---|---|
| Basic meaning | Natural organ-derived peptide complex. | Synthesized short peptide, usually a di-, tri-, or tetrapeptide. |
| Sequence clarity | Usually not one defined sequence. | Often has a concise sequence such as AEDG, EDR, KED, or EW. |
| SEO risk | People may treat product names as if they were molecule names. | People may assume sequence identity proves clinical effect. |
| How this site uses it | Name and tissue-target mapping only. | Sequence and source mapping, with evidence caveats. |
Examples by tissue target
| Target context | Natural complex example | Synthetic short-peptide example |
|---|---|---|
| Pineal / neuroendocrine | Endoluten | Epitalon / Epithalon (AEDG) |
| Thymus / immune | Vladonix | Thymogen (EW) |
| Brain / nervous system | Cerluten | Pinealon (EDR), Cortagen (AEDP) |
| Vascular system | Ventfort | Vesugen / Vezugen (KED) |
| Liver | Svetinorm | Ovagen (EDL), Livagen (KEDA) |
Where Cytamins and cytomedins fit
You may also see Cytamin, Cytamins, or cytomedins around Russian peptide bioregulator and organ-extract supplement discussions. Treat these as nearby terminology that needs source verification, not as precise synonyms for Cytomax, Cytogen, or a defined amino-acid sequence.
A practical keyword rule: Cytomax usually points to a natural organ peptide complex, Cytogen usually points to a synthetic short peptide, and cytomedin is an older biological-regulation term. Cytamin searches may overlap with supplement catalog language rather than a single molecular identity.
| Term | How to interpret the search | Evidence caution |
|---|---|---|
| Cytomax / Cytomaxes | Usually a natural organ-derived peptide-complex product family. | Not a single sequence, and not proof of clinical benefit. |
| Cytogen / Cytogens | Usually a synthesized short-peptide family such as AEDG, EDR, KED, or EW. | Sequence identity does not prove a consumer product is safe or effective. |
| Cytamin / Cytamins | Often supplement-catalog terminology around organ extracts. | Verify the specific product, country, label, and manufacturer. |
| cytomedin / cytomedins | Older tissue-regulation terminology in the Russian peptide bioregulator literature. | Useful for source tracing, not for dosage or legal-status conclusions. |
FDA status and legal status limits
A catalog can tell you how a seller organizes names. It cannot establish that a product is correctly manufactured, clinically proven, FDA-approved, sterile, safe for injection, legal to market, or appropriate for a health condition. FDA approval, compounding status, supplement labeling, research-use labeling, and import status are separate questions that must be checked for a specific product and jurisdiction.
Sources
- e-Peptide Cytomax list - commercial list used for product-family names and tissue targets only.
- e-Peptide Cytogen list - commercial list used for synthesized-peptide family terminology only.
- Khavinson, "Peptides, Genome, Aging" (2014) - source for synthetic short-peptide sequences.
- FDA: how to check whether a drug is approved - U.S. legal-status verification context.
- FDA compounding Q&A - U.S. safety, effectiveness, quality, and approval context.
- MedlinePlus: Evaluating Health Information - framework for source and funding scrutiny.